Navigation Links
Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerix's Lead Antiviral CMX001
Date:2/24/2011

DURHAM, N.C., Feb. 24, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus (AdV) infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.  Oral CMX001 was administered under an Emergency Investigational New Drug Application (EIND) to a severely immunocompromised pediatric stem cell patient following the patient's failure to respond to prior treatment with intravenous cidofovir.  Data from this case report were published in the February edition of the Journal of Clinical Virology.

"Cases such as this highlight the life-saving potential of CMX001 to successfully and safely resolve severe viral infections.  Data generated from Chimerix's clinical studies and numerous EIND cases in which CMX001 has been used to combat the full spectrum of double-stranded DNA viruses have greatly informed our late-stage clinical development plans," said Wendy Painter, M.D., Chief Medical Officer of Chimerix.  "We see a unique opportunity to develop this drug for the prevention and treatment of viral infections that are frequently fatal to transplant patients.  In particular, the lack of viable treatment options in the pediatric patient population must be rapidly addressed and we are preparing to initiate a Phase 2 clinical study in pediatric and adult transplant patients with adenovirus infections."

CMX001 is being developed by Chimerix for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients and as a medical countermeasure in the event of a smallpox release.  Chimerix is currently conducting a Phase 2 dose-defining clinical study of CMX001 in immunocompromised hematopoietic stem cell transplant patients at risk of life-threatening infection with cytomegalovirus.  Chimerix is init
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%
2. Reportlinker Adds Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
3. Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
6. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
7. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
8. Crothall Healthcare Selects 3M™ Clean-Trace™ for Infection Control Verification
9. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
10. Sage Products and 3M Infection Prevention Announce Agreement
11. Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
(Date:9/18/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced the first presentation of positive safety and ... Investigation of Collagenase Optimizing the Resolution of Dupuytrens) ... histolyticum (CCH) for the treatment of two Dupuytren,s ... the study examined expanded flexibility with timing of ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 6Auxilium Pharmaceuticals, Inc. Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 7
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, ... common antidepressant can quickly alter the way brain cells communicate ... online Sept. 18 in Current Biology , are ... prescribed antidepressants. Experts said the hope is to eventually be ... benefit from a drug -- and which people would fare ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... Texas (PRWEB) September 19, 2014 ... Inside the Neighborhood Mission (Misión Barrio Adentro), ... of the healthcare system (see Section 6.1.3.). ... billion) in an Autonomous Service of Pharmaceutical ... production plant, which provides medicines at a ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Thousands of ... be recognizing their shared fundraising impact on 127 member ... 25. , The first-ever Dance Marathon Day will officially ... million projected to be raised by college and high ... Hospital. Donations generated through Dance Marathon campus programs help ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2
... arms to snip away tumors , TUESDAY, Dec. 18 ... promise in the removal of cancer involving the tonsils, ... University of Pennsylvania, the transoral robotic surgery (TORS) system ... with an endoscope, an optical instrument with two video ...
... in the December issue of The Journal of the ... cancer operations in 80-year-olds are considerably worse than reported ... lead to unrealistic expectations about the safety of these ... patients and their physicians may have difficulty accurately assessing ...
... Calif., Dec. 18 BioMarin,Pharmaceutical Inc. (Nasdaq and ... Canadian rights for tetrahydrobiopterin (BH4), including,Kuvan(TM) (sapropterin dihydrochloride), ... Germany. Kuvan is an oral small molecule for ... Merck,Serono. Based on published literature, there are approximately ...
... 18 Art Mellor is one of,more than 400,000 ... from,Multiple Sclerosis (MS). It,s, a debilitating disease that causes,paralysis, ... no wonder that Mellor, the founder of the Accelerated,Cure ... and more,interested in raising the funds he needs to ...
... Southwestern Medical Center researchers have found that the existing body ... of obese patients at risk of cardiovascular disease. , ... Surgery for Obesity and Related Diseases, is among ... index (BMI) and cardiovascular disease as it relates to bariatric ...
... and Implantability Characteristics, MINNEAPOLIS, Dec. 18 ... manufacturer and marketer of state-of-the-art cardiac,surgery products ... Drug,Administration (FDA) approval for the ATS Open ... http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), The ATS AP360 heart ...
Cached Medicine News:Health News:Robotic Surgery Treats Tonsil Cancer 2Health News:Study finds outcomes of high-risk cancer operations in 80-year-olds worse than reported 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 2Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 3Health News:BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono 4Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 2Health News:This Holiday Season Some Dream of a White Christmas - The Accelerated Cure Project Dreams of Developing a Cure for Multiple Sclerosis 3Health News:BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 2Health News:ATS Medical Receives FDA Approval for AP360 Mechanical Heart Valve 3
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
Inquire...
Medicine Products: